AI-powered search

Live Evaluations

ADCS Advanced Therapeutic Update: June 11, 2024

About

Advanced Therapeutic Update CME Session

Tuesday, June 11, 2024

8 PM ET / 5 PM PT

Part I: From Patchy to Precise: Enhancing Alopecia Areata Management High Risk Cutaneous SCC: Staging and Treating


Part II: High Risk Cutaneous SCC: Staging and Treating

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Recognize the two key trichoscopy findings of alopecia areata

  • Evaluate when and how to incorporate oral minoxidil, pulsed dexamethasone, and oral JAK inhibitors in advanced cases of alopecia areata

  • Identify which SCC tumors are defined as ‘high risk’

  • Discuss with patients why their tumor may need more than just surgery

  • Implement management strategies to more closely monitor patients with high risk SCC

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
Spencer
Spencer Hawkins, MD, FAAD

Double Board-Certified Dermatologist

Mohs Micrographic Surgeon

Advanced Dermatology and Cosmetic Surgery

East Greenwich, RI

Mark
Mark Kaufmann, MD

Chief Medical Officer, Advanced Dermatology and Cosmetic Surgery
Clinical Professor, Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Juan-Carlos
Juan-Carlos Martinez, MD

Mohs Micrographic Surgery Specialist

Advanced Dermatology and Cosmetic Surgery 

Jacksonville Beach, FL

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

Disclosures are as follows:

Spencer Hawkins, MD, FAAD

Advisory Board/Consultant: Voluntus

Employee/Owner: Owner of Hair Medicine Institute, LLC 

Mark D. Kaufmann, MD

Consultant: Apogee Therapeutics, Avita Medical, Biofrontera, Dermagnostix, Dermtech,Incyte, Novan, Novartis, Rise Healthcare, Rivera Consulting, UCB, Verrica

Ownership Interest (privately held): Modernizing Medicine, Molesafe

Juan-Carlos Martinez, MD

No relevant financial relationships with any Ineligible Company in the past 24 months.

The Institute discloses that all relevant conflicts have been satisfactorily mitigated.


Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved